Safety Shot Provides Update On Litigation
Portfolio Pulse from Benzinga Newsdesk
Safety Shot, Inc. (NASDAQ:SHOT) is engaged in litigation against Capybara Research and Benzinga for publishing and republishing content deemed harmful to the company and its investors. SHOT's CEO, Brian S John, is determined to pursue legal action against those involved in 'short and distort' campaigns. The company has enlisted The Basile Law Firm P.C., known for combating dilution funding, to assist in these legal efforts. The firm has a history of success in similar cases and is actively involved in RICO actions against dilution funders.
December 05, 2023 | 1:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Safety Shot, Inc. is pursuing legal action against Capybara Research and Benzinga for publishing harmful content. The company's aggressive stance against market manipulation and enlistment of The Basile Law Firm P.C. could reassure investors and potentially mitigate negative sentiment.
The announcement of legal action against entities allegedly spreading false information could be seen positively by investors, as it shows the company's commitment to defending its reputation and investor interests. The involvement of The Basile Law Firm P.C., with its track record, may further instill confidence in the company's ability to handle such disputes. This could lead to a short-term positive impact on SHOT's stock price as the market reacts to the company's proactive measures.
CONFIDENCE 75
IMPORTANCE 85
RELEVANCE 100